Biotech Values

[biotech_researcher]

Quote:
...”the key is [EOLS] are not racing to the bottom here for market share in terms of pricing which is good for all the [botulinum-toxin] players...
Right. Net of discounts, Jeuveau's price will be comparable to Dysport an”

It might be a little early to claim victory with this point, imo. You’ve got 3-4 companies now selling in the cosmetic space, with two more competitors being added over the next 18 months. That kind of competition can do disruptive things to pricing.

Therapeutics may be the place for RVNC